200909 - Quarter 2

Status of Investor Complaints for the quarter ended September 30,
2009

Complaints Pending at
the beginning of the quarter		Nil

Complaints Received during
the quarter
				07

Complaints disposed off during the quarter
			07

Complaints unresolved at the
end of the quarter 		Nil

1. The above financial results of the
company have been reviewed by
the Audit Committee and approved by the Board of Directors at their
meeting held on October 28, 2009
and have been subjected to a Limited Review by the Statutory Auditors
of the Company.

2. On
May 28, 2008 Alkaloida Chemical Company Exclusive Group Limited
(Alkaloida), a subsidiary of the
Company which has made a strategic investment in Taro Pharmaceutical
Industries Limited (Taro) a
pharmaceutical company incorporated in Israel received a notice from
Taro regarding purported
termination of the merger agreement between Taro,Alkalodia and Aditya
Acquisition Company Ltd, an
Israeli incorporated subsidiary of Alkaloida. On the same date, Taro
and some of its directors had
filed for a declaratory judgment in an Israeli court seeking
Alkaloida/Sun Pharma to conduct a
special tender offer which has been rejected by the Tel-Aviv District
Court. The plaintiffs have
appealed this decision in the Supreme Court of Israel which has
temporarily prohibited closing of
the Tender offer until it issues a decision on the appeal. Alkaloida
does not foresee any adverse
impact on its investment.

3. The Company has only one
reportable business segment namely
´Pharmaceuticals´.

4. Tax Expense includes
Current Tax, Deferred Tax and
Fringe Benefit Tax.

5. Figures for the previous period / year 
have been regrouped /
reclassified, wherever considered necessary.

Dilip S
Shanghvi
Chairman and Managing
Director